Yeast "N"-hybrid systems for protein-protein and drug-protein interaction discovery.
The majority of small molecule drugs act on protein targets to exert a therapeutic function. It has become apparent in recent years that many small molecule drugs act on more than one particular target and consequently, approaches which profile drugs to uncover their target binding spectrum have become increasingly important. Classical yeast two-hybrid systems have mainly been used to discover and characterize protein-protein interactions, but recent modifications and improvements have opened up new routes towards screening for small molecule-protein interactions. Such yeast "n"-hybrid systems hold great promise for the development of drugs which interfere with protein-protein interactions and for the discovery of drug-target interactions. In this review, we discuss several yeast two-hybrid based approaches with applications in drug discovery and describe a protocol for yeast three-hybrid screening of small molecules to identify their direct targets.
Dualsystems Biotech AG, Grabenstrasse 11a, 8952 Schlieren, Switzerland.
Mandana
M
Rezwan
Daniel
D
Auerbach
D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D015723:Gene Library; D006801:Humans; D011485:Protein Binding; D011506:Proteins / Q000378:metabolism*; D054852:Small Molecule Libraries; D020798:Two-Hybrid System Techniques
D011506:Proteins; D054852:Small Molecule Libraries